Michael J. Darsley
10Patents
3h-index
16Co-inventors
53Inventor score
Filing activity: Sep 17, 1993 → Mar 28, 2011
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5855885A | Isolation and production of catalytic antibodies using phage technology | Chemistry; Metallurgy | 50 | Expired |
| US5597573A | Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities | Human Necessities | 11 | Expired |
| US5593969A | Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors | Human Necessities | 10 | Expired |
| US7943122B2 | Attenuated bacteria useful in vaccines | Emerging Cross-Sectional Technologies | 3 | Active |
| US7951361B2 | Bacterial vaccine | Emerging Cross-Sectional Technologies | 3 | Active |
| US5891648A | Reaction-based selection for expression of and concentration of catalytic moieties | Physics | 2 | Expired |
| US6177270A | Reaction-based selection for expression of and concentration of catalytic moieties | Physics | 1 | Expired |
| US6121007A | Reaction-based selection for expression of and concentration of catalytic moieties | Physics | 1 | Expired |
| US5631137A | Reaction-based selection for expression of and concentration of catalytic moieties | Physics | 1 | Expired |
| US8318148B2 | Attenuated bacteria useful in vaccines | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.